Home  »  Stock   »  AbCellera Biologics Inc.’s Bumpy Road: Analy...

AbCellera Biologics Inc.’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects

At present, AbCellera Biologics Inc. (ABCL) has a stock price of $6.61. In the previous session, the stock saw a rise, peaking at $6.68 after an opening price of $5.84. The day’s lowest price was $5.755, and it closed at $5.84.

AbCellera Biologics Inc. ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $14.97 on 11/15/22, while the lowest value for the same period was recorded at $5.53 on 05/09/23.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


52-week price history of ABCL Stock

A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. AbCellera Biologics Inc.’s current trading price is -55.85% away from its 52-week high, while its distance from the 52-week low is 19.53%. The stock’s price range during this period has spanned from $5.53 to $14.97. In the Healthcare sector, the AbCellera Biologics Inc.’s shares surpassed a trading volume of approximately 5.69 million for the day, which was noticeably higher compared to the average daily volume of 9.1.79 million over the past three months.

Market Capitalization and Financial Performance: An In-Depth Look

AbCellera Biologics Inc. (ABCL) has experienced a quarterly decline of -25.65% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.91B and boasts a workforce of 495 employees.

A Closer Look at Analysts’ Ratings for AbCellera Biologics Inc.

As of right now, 11 analysts are rating AbCellera Biologics Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 8.26, with a change in price of -2.87. Similarly, AbCellera Biologics Inc. recorded 1,760,491 in trading volume during the last 100 days, posting a change of -30.27%.

Examining ABCL’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ABCL stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.

ABCL Stock Stochastic Average

Today’s raw stochastic average for AbCellera Biologics Inc. over the last 50 days is 47.79%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 68.35%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 34.64% and 22.22%, respectively.

ABCL Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a loss of -34.75%.However, over the last six months, we can see a stronger performance of -53.05%. Over the last 30 days, the price of ABCL has leaped by -8.32%. And in the last five days, it has surged by 10.54%.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts